137 related articles for article (PubMed ID: 21334454)
1. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
[TBL] [Abstract][Full Text] [Related]
3. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
[TBL] [Abstract][Full Text] [Related]
4. Hunter syndrome: Long-term idursulfase treatment does not protect patients against DNA oxidation and cytogenetic damage.
Diaz Jacques CE; de Souza HM; Sperotto NDM; Veríssimo RM; da Rosa HT; Moura DJ; Saffi J; Giugliani R; Vargas CR
Mutat Res Genet Toxicol Environ Mutagen; 2018 Nov; 835():21-24. PubMed ID: 30249478
[TBL] [Abstract][Full Text] [Related]
5. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients.
Manfredini V; Biancini GB; Vanzin CS; Dal Vesco AM; Cipriani F; Biasi L; Treméa R; Deon M; Peralba Mdo C; Wajner M; Vargas CR
Cell Biochem Funct; 2010 Jul; 28(5):360-6. PubMed ID: 20589733
[TBL] [Abstract][Full Text] [Related]
7. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
8. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
9. Hunter disease before and during enzyme replacement therapy.
Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic biomonitoring in mucopolyssacharosis I, II and IV patients treated with enzyme replacement therapy.
Guilheiro JM; Chaves MD; Martins AM; Ribeiro DA; D'Almeida V
Toxicol Mech Methods; 2014 Dec; 24(8):603-7. PubMed ID: 25141890
[TBL] [Abstract][Full Text] [Related]
11. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients.
Sitta A; Manfredini V; Biasi L; Treméa R; Schwartz IV; Wajner M; Vargas CR
Mutat Res; 2009; 679(1-2):13-6. PubMed ID: 19665577
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease.
Mutlu-Türkoğlu U; Akalin Z; Ilhan E; Yilmaz E; Bilge A; Nişanci Y; Uysal M
Clin Biochem; 2005 Dec; 38(12):1059-65. PubMed ID: 16226736
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
[TBL] [Abstract][Full Text] [Related]
14. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass.
Ceylan E; Kocyigit A; Gencer M; Aksoy N; Selek S
Respir Med; 2006 Jul; 100(7):1270-6. PubMed ID: 16307872
[TBL] [Abstract][Full Text] [Related]
15. Functional capacity evaluation of patients with mucopolysaccharidosis.
Guarany NR; Schwartz IV; Guarany FC; Giugliani R
J Pediatr Rehabil Med; 2012; 5(1):37-46. PubMed ID: 22543891
[TBL] [Abstract][Full Text] [Related]
16. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
[TBL] [Abstract][Full Text] [Related]
17. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
[TBL] [Abstract][Full Text] [Related]
18. Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers.
Lin SP; Chang JH; Lee-Chen GJ; Lin DS; Lin HY; Chuang CK
Clin Chim Acta; 2006 Jul; 369(1):29-34. PubMed ID: 16480701
[TBL] [Abstract][Full Text] [Related]
19. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
[No Abstract] [Full Text] [Related]
20. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
